Protagen, NMI Developing Assays for Autoimmune Diseases, Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen and the Natural and Medical Sciences Institute at the University of Tubingen announced they will be developing multiplex assays for the diagnosis of autoimmune diseases and cancer.

The deal will leverage Protagen's expertise in the high-throughput expression of human proteins and clinical validation studies, and the institute's research platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.